Abstract
Erectile dysfunction occurs extensively among patients with arterial hypertension. We investigated the safety of sildenafil for patients with and without antihypertensive medication. Our study included data from 35 double-blind, placebo- controlled, and randomized investigations, with a total of 8115 patients. The term of therapy was between 6 weeks and 6 months, for both the sildenafil group (5-200 mg, n = 4819) as well as the placebo group (n = 3296). We studied the adverse events in the men who received 1 or more hypertensives (n = 2388), and in those who took no antihypertensive medication (n = 5727). Our findings disclosed equal frequency of adverse events in both groups, without influence by the number of different antihypertensives administered. The occurrence of AEs associated with blood pressure was slight, and was comparable between the individual groups. These results support the conclusion that sildenafil is also well tolerated by patients taking one or more antihypertensives. Patients being treated with alpha blockers should be stable on this therapy in order to minimize the possibility of orthostatic hypotension. An initial dose of 25 mg should furthermore be considered for these patients.
Keywords: endothelium, antihypertensives, nitric oxide, c-GMP, hypotonsion
Current Drug Safety
Title: Sildenafil is Well Tolerated by Erectile Dysfunction Patients Taking Antihypertensive Medications, Including Those on Multidrug Regimens
Volume: 2 Issue: 1
Author(s): Marko Bohm, Martin Burkart and Gert Baumann
Affiliation:
Keywords: endothelium, antihypertensives, nitric oxide, c-GMP, hypotonsion
Abstract: Erectile dysfunction occurs extensively among patients with arterial hypertension. We investigated the safety of sildenafil for patients with and without antihypertensive medication. Our study included data from 35 double-blind, placebo- controlled, and randomized investigations, with a total of 8115 patients. The term of therapy was between 6 weeks and 6 months, for both the sildenafil group (5-200 mg, n = 4819) as well as the placebo group (n = 3296). We studied the adverse events in the men who received 1 or more hypertensives (n = 2388), and in those who took no antihypertensive medication (n = 5727). Our findings disclosed equal frequency of adverse events in both groups, without influence by the number of different antihypertensives administered. The occurrence of AEs associated with blood pressure was slight, and was comparable between the individual groups. These results support the conclusion that sildenafil is also well tolerated by patients taking one or more antihypertensives. Patients being treated with alpha blockers should be stable on this therapy in order to minimize the possibility of orthostatic hypotension. An initial dose of 25 mg should furthermore be considered for these patients.
Export Options
About this article
Cite this article as:
Bohm Marko, Burkart Martin and Baumann Gert, Sildenafil is Well Tolerated by Erectile Dysfunction Patients Taking Antihypertensive Medications, Including Those on Multidrug Regimens, Current Drug Safety 2007; 2 (1) . https://dx.doi.org/10.2174/157488607779315462
DOI https://dx.doi.org/10.2174/157488607779315462 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Naturally Occurring and Related Synthetic Cannabinoids and their Potential Therapeutic Applications
Recent Patents on CNS Drug Discovery (Discontinued) Pathophysiology and Treatment of Obesity Hypertension
Current Pharmaceutical Design Ligand-Based Peptide Design and Combinatorial Peptide Libraries to Target G Protein-Coupled Receptors
Current Pharmaceutical Design Interventions Against Sarcopenia in Older Persons
Current Pharmaceutical Design Current Management of Traumatic Rupture of the Descending Thoracic Aorta
Current Cardiology Reviews Apelin in the Control of Body Fluid Homeostasis and Cardiovascular Functions
Current Pharmaceutical Design Diabetes and Its Complications: Therapies Available, Anticipated and Aspired
Current Diabetes Reviews Cognitive Impairment in the Septic Brain
Current Neurovascular Research Therapeutic Perspectives of Inhibitors of Endocannabinoid Degradation
Current Drug Targets - CNS & Neurological Disorders Use and Safety of Calcium Channel Blockers in Obstetrics
Current Medicinal Chemistry Implementation of Cardiovascular Disease Prevention Guidelines into Clinical Practice: an Unmet Challenge?
Current Pharmaceutical Design Therapeutic Prospects for Parathyroid Hormone and Parathyroid Hormone Analogs
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents The Medicinal Chemistry of Nitrite as a Source of Nitric Oxide Signaling
Current Topics in Medicinal Chemistry MDR1/P-Glycoprotein (ABCB1) as Target for RNA Interference-Mediated Reversal of Multidrug Resistance
Current Drug Targets Effects of Alcohol in the Lung
Current Respiratory Medicine Reviews Clinical Efficacy of Remdesivir and Favipiravir in the Treatment of COVID-19 Patients: Scenario so far
Current Drug Research Reviews Potential Therapeutic Benefits of Dipyridamole in COVID-19 Patients
Current Pharmaceutical Design Guanylation of Amines with Isonitriles in the Presence of Iodine
Letters in Organic Chemistry A Yeast Extract High in Bioactive Peptides has a Blood-Pressure Lowering Effect in Hypertensive Model
Current Medicinal Chemistry TRPV4 Agonists and Antagonists
Current Topics in Medicinal Chemistry